News for Tonix Pharmaceuticals Holding Corp. (0A4T.L)

The FDA decision on PharmaTher Holdings' resubmitted Abbreviated New Drug Application for racemic ketamine KETARX is due on August 9, 2025..

Tonix Pharmaceuticals (TNXP) has announced the introduction of the Move Fibro Forward initiative through its commercial arm, Tonix Medicines, Inc. This campaign

CHATHAM, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. ( TNXP), a fully-integrated biotechnology company, today announced that T

Tonix Pharmaceuticals stock surged by 10% after promising Phase 3 trial results. Analysts set a bullish average price target of $61.67, indicating signi

Tonix Pharmaceuticals (TNXP) has released the full results from its Phase 3 RESILIENT trial for TNX-102 SL, targeting fibromyalgia management. These results wer

The previously disclosed and now published RESILIENT data show that once-nightly TNX-102 SL achieved statistically significant improvement in the primary endpoint of reducing fibromyalgia pain versus placebo, and was generally well tolerated

Tonix Pharmaceuticals (TNXP) to present new TNX-801 vaccine data at the Vaccine Congress 2025. TNX-801 shows promising preclinical results for mpox and smal

Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox TNX-801 confers durable protection af

Combination treatment of mTNX-1700 (mTFF2-MSA fusion protein) with anti-PD1 antibody was associated with increased survival and decreased metastases in animal models of gastric cancer relative to anti-PD1 treatment alone

CHATHAM, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company, today announced that it will be added to the broad-market Russell 3000® Index, with automatic inclusion in the small-cap Russell 2000® Index, after the open of U.S. equity markets today, June 30, 2025, as part of the 2025 Russell indexes reconstitution.

Discover why Tonix Pharmaceuticals Holding Corp. stock could rally with FDA approval for Tonmya targeting fibromyalgia. Click for more on TNXP.

Tonix Pharmaceuticals (TNXP) showcased promising data at the Annual European Congress of Rheumatology, EULAR, held in Barcelona, Spain, between June 11 and 14,

Tonix Pharmaceuticals (TNXP) presented promising data for TNX-102 SL at EULAR 2025, showing significant pain reduction in fibromyalgia patients. The FDA h

**media[653948]**

U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Thursday. Shares of Oxford Industries, Inc. OXM fell sharply i...

Creative Global Technology Holdings Limited (CGTL) is up over 54 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Tonix Pharmaceuticals (TNXP) to present at the 2025 BIO International Convention in Boston on June 16, 2025. FDA review of TNX-102 SL for fibromyalgia with

CHATHAM, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. ( TNXP) (Tonix or the Company), a fully-integrated biotechnology company

**media[650499]**